Skip to main content

Table 2 Characteristics of endoscopic submucosal dissection procedures

From: A randomized controlled trial of endoscopic steroid injection for prophylaxis of esophageal stenoses after extensive endoscopic submucosal dissection

  Treatment group Control group p-value
n = 16 n = 16
Size of carcinoma, mm mean ± SD (range) 58 ± 16 (28–92) 53 ± 19 (30–90) 0.40
Size of resected specimen, mm mean ± SD (range) 68 ± 14 (43–97) 62 ± 17 (39–101) 0.29
Depth of invasion, n (m1/m2/m3/sm1/sm2*) 2/11/2/0/1 2/6/6/0/2 0.35
Operation time, min mean ± SD (range) 89.6 ± 37.5 (36–176) 88.3 ± 44.5 (44–235) 0.93
Pathological margin free, n (%) 15 (93.8) 15 (93.8) 0.99
Mucosal defect of circumference, n (<75% / ≥75%) 11/5 11/5 0.99
Perforation by ESD, n (%) 0/16 (0) 0/16 (0) 0.55
  1. Abbreviations: m1, carcinoma in situ; m2, intramucosal invasive carcinoma limited to the lamina propria mucosa; m3, carcinoma limited to the muscularis mucosa; sm2, submucosal invasion between sm1 (slight invasion less than 200 μm in depth) and sm3 (massive invasion); SD, standard deviation; ESD, endoscopic submucosal dissection.
  2. *Three patients with sm2 invasion had relative contraindications for surgical intervention for one or more of the following reasons: age considerations (the patients were 76, 79 and 89 years old), serious medical conditions (cerebral vascular disease, multiple primary cancers, low performance status), and/or patients’ decisions to decline surgery. A treatment plan for these patients was carefully chosen under full informed consent.